Vident Advisory LLC Grows Stake in Grifols, S.A. $GRFS

Key Points

• Vident Advisory LLC increased its stake in Grifols, S.A. by 134.5% during the 1st quarter, now owning 69,564 shares valued at $495,000.
• Grifols recently declared a special dividend of $0.1404 paid on August 20th, reflecting a payout ratio of 11.97%.
• The stock price of Grifols has risen by 2.3% recently, with a current price of $10.13 and an average price target of $10.30 from analysts.

Vident Advisory LLC raised its stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 134.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,564 shares of the biotechnology company's stock after acquiring an additional 39,902 shares during the quarter. Vident Advisory LLC's holdings in Grifols were worth $495,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Groupe la Francaise bought a new position in Grifols during the 1st quarter worth approximately $1,699,000. Atlas Capital Advisors Inc. increased its holdings in Grifols by 3,948.1% during the first quarter. Atlas Capital Advisors Inc. now owns 30,118 shares of the biotechnology company's stock worth $214,000 after buying an additional 29,374 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Grifols by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company's stock worth $328,000 after buying an additional 2,026 shares during the last quarter. Highland Peak Capital LLC increased its holdings in shares of Grifols by 24.1% in the first quarter. Highland Peak Capital LLC now owns 975,835 shares of the biotechnology company's stock valued at $6,938,000 after purchasing an additional 189,625 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Grifols by 20.3% in the first quarter. Natixis Advisors LLC now owns 212,585 shares of the biotechnology company's stock valued at $1,511,000 after purchasing an additional 35,865 shares during the last quarter.

Grifols Price Performance

Shares of GRFS traded up $0.17 during midday trading on Thursday, hitting $10.02. 301,355 shares of the company traded hands, compared to its average volume of 942,464. Grifols, S.A. has a one year low of $6.19 and a one year high of $11.14. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The firm has a market cap of $6.89 billion, a P/E ratio of 8.58, a PEG ratio of 0.34 and a beta of 0.64. The stock has a 50-day moving average of $10.06 and a 200-day moving average of $8.61.

Grifols Dividend Announcement

The company also recently announced a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio is currently 11.97%.

Analyst Ratings Changes

GRFS has been the topic of a number of recent research reports. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a research note on Monday, July 7th. Zacks Research raised shares of Grifols to a "hold" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Grifols in a report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.30.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.